{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:04:17Z","timestamp":1753182257947,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Commission of Henan Province","award":["number 2018020423"],"award-info":[{"award-number":["number 2018020423"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To investigate the efficacy and safety of interval debulking surgery (IDS) combined with dense hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in Chinese patients with FIGO stage III serous epithelial ovarian cancer (EOC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective single-center study reviewed the demographic and clinical data of 197 patients with primary FIGO stage III serous EOC who were treated with IDS with (<jats:italic>n<\/jats:italic>\u2009=\u2009121) or without (<jats:italic>n<\/jats:italic>\u2009=\u200976, control group) dense HIPEC between January 2012 and April 2017. The co-primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoint was the occurrence of adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median PFS was 24\u2009months in the IDS plus dense HIPEC group, whereas it was 19\u2009months in the IDS alone group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.33\u20130.65, <jats:italic>p<\/jats:italic>\u2009=\u20090.000). The median OS in patients treated with IDS plus dense HIPEC (51\u2009months) was significantly longer than that in patients treated with IDS alone (40\u2009months, HR 0.52, 95% CI: 0.35\u20130.78, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). The demographic and preoperative clinical characteristics of these two groups were comparable (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). In the IDS alone group, no adverse events were recorded in 42 (55.3%) of the 76 patients, and 14 (18.4%) patients were reported to have grade III\/IV adverse events. In the IDS plus dense HIPEC group, no adverse events were recorded in 55 (45.5%) of the 121 patients, and 23 (19.0%) patients were reported to have grade III\/IV adverse events. No postoperative deaths occurred within 30\u2009days in either group and neither did severe fatal complications in the IDS plus dense HIPEC group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IDS plus dense HIPEC with cisplatin in Chinese patients with FIGO stage III serous EOC is associated with improved survival and is reasonably well tolerated by patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08507-y","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T13:02:27Z","timestamp":1624798947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiaoli","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danwei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-9579","authenticated-orcid":false,"given":"Yongxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"issue":"4","key":"8507_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"8507_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332. https:\/\/doi.org\/10.3322\/caac.21338.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"8507_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","volume":"118","author":"RE Bristow","year":"2010","unstructured":"Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118(3):262\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2010.05.025.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8507_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/IGC.0b013e31819915cb","volume":"19","author":"C Marth","year":"2009","unstructured":"Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevelda P. Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology. Int J Gynecol Cancer. 2009;19(1):94\u2013102. https:\/\/doi.org\/10.1111\/IGC.0b013e31819915cb.","journal-title":"Int J Gynecol Cancer"},{"issue":"32","key":"8507_CR5","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1200\/JCO.2016.69.7458","volume":"34","author":"IB Vergote","year":"2016","unstructured":"Vergote IB, Van Nieuwenhuysen E, Vanderstichele A. How to select neoadjuvant chemotherapy or primary Debulking surgery in patients with stage IIIC or IV ovarian carcinoma. J Clin Oncol. 2016;34(32):3827\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.69.7458.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8507_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353. https:\/\/doi.org\/10.1056\/NEJMoa0908806.","journal-title":"N Engl J Med"},{"issue":"1","key":"8507_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","volume":"143","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline. Gynecol Oncol. 2016;143(1):3\u201315. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.022.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8507_CR8","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.3802\/jgo.2018.29.e53","volume":"29","author":"M Ceresoli","year":"2018","unstructured":"Ceresoli M, Verrengia A, Montori G, Busci L, Coccolini F, Ansaloni L, et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study. J Gynecol Oncol. 2018;29(3):e53. https:\/\/doi.org\/10.3802\/jgo.2018.29.e53.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"8507_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.21873\/anticanres.14092","volume":"40","author":"M Friedrich","year":"2020","unstructured":"Friedrich M, Zinn W, Kolnsberg L, Kraft C, Kuhn W. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian Cancer: evaluation of side effects in a single institution cohort. Anticancer Res. 2020;40(3):1481\u20136. https:\/\/doi.org\/10.21873\/anticanres.14092.","journal-title":"Anticancer Res"},{"issue":"2","key":"8507_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112(2):306\u201312. https:\/\/doi.org\/10.1038\/bjc.2014.602.","journal-title":"Br J Cancer"},{"issue":"6","key":"8507_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s11095-017-2132-4","volume":"34","author":"F Coccolini","year":"2017","unstructured":"Coccolini F, Acocella F, Morosi L, Brizzola S, Ghiringhelli M, Ceresoli M, et al. High penetration of paclitaxel in Abdominal Wall of rabbits after Hyperthermic intraperitoneal Administration of nab-Paclitaxel Compared to standard paclitaxel formulation. Pharm Res. 2017;34(6):1180\u20136. https:\/\/doi.org\/10.1007\/s11095-017-2132-4.","journal-title":"Pharm Res"},{"key":"8507_CR12","doi-asserted-by":"crossref","unstructured":"Riggs MJ, Pandalai PK, Kim J, Dietrich CS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Diagnostics. 2020;10(1).","DOI":"10.3390\/diagnostics10010043"},{"issue":"2","key":"8507_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-017-3376-8","volume":"80","author":"AA Mendivil","year":"2017","unstructured":"Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL, et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017;80(2):405\u201310. https:\/\/doi.org\/10.1007\/s00280-017-3376-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"8507_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic Intraperitoneal Chemotherapy in ovarian Cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med"},{"issue":"1","key":"8507_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13048-019-0509-1","volume":"12","author":"G Zhang","year":"2019","unstructured":"Zhang G, Zhu Y, Liu C, Chao G, Cui R, Zhang Z. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. J Ovarian Res. 2019;12(1):33. https:\/\/doi.org\/10.1186\/s13048-019-0509-1.","journal-title":"J Ovarian Res"},{"issue":"6","key":"8507_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejso.2010.04.005","volume":"36","author":"C Pomel","year":"2010","unstructured":"Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol. 2010;36(6):589\u201393. https:\/\/doi.org\/10.1016\/j.ejso.2010.04.005.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"8507_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","volume":"41","author":"YR Huo","year":"2015","unstructured":"Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578\u201389. https:\/\/doi.org\/10.1016\/j.ejso.2015.08.172.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"8507_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ejso.2011.03.134","volume":"37","author":"PA Cascales Campos","year":"2011","unstructured":"Cascales Campos PA, Gil Martinez J, Galindo Fernandez PJ, Gil Gomez E, Martinez Frutos IM, Parrilla Paricio P. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol. 2011;37(6):543\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2011.03.134.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"8507_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/aogs.12577","volume":"94","author":"J Delotte","year":"2015","unstructured":"Delotte J, Arias T, Guerin O, Boulahssass R, Bereder I, Bongain A, et al. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women. Acta Obstet Gynecol Scand. 2015;94(4):435\u20139. https:\/\/doi.org\/10.1111\/aogs.12577.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6","key":"8507_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/jso.23688","volume":"110","author":"T Safra","year":"2014","unstructured":"Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014;110(6):661\u20135. https:\/\/doi.org\/10.1002\/jso.23688.","journal-title":"J Surg Oncol"},{"key":"8507_CR21","doi-asserted-by":"crossref","unstructured":"Antonio CCP, Francisco-Cristobal MC, Alida GG, Susana SG, Israel M, Rafael M, et al. Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer. Clin Exp Metastasis. 2019.","DOI":"10.1007\/s10585-019-10010-5"},{"issue":"9","key":"8507_CR22","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00432-014-1692-5","volume":"140","author":"M Ba","year":"2014","unstructured":"Ba M, Long H, Zhang X, Tang Y, Wu Y, Yu F, et al. Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites. J Cancer Res Clin Oncol. 2014;140(9):1497\u2013506. https:\/\/doi.org\/10.1007\/s00432-014-1692-5.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"8507_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","volume":"122","author":"M Deraco","year":"2011","unstructured":"Deraco M, Kusamura S, Virzi S, Puccio F, Macri A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.004.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8507_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","volume":"133","author":"DG Mutch","year":"2014","unstructured":"Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.013.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"8507_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355. https:\/\/doi.org\/10.1097\/00000421-198212000-00014.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"8507_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","volume":"25","author":"LB Wenzel","year":"2007","unstructured":"Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2007;25(4):437\u201343. https:\/\/doi.org\/10.1200\/JCO.2006.07.3494.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8507_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","volume":"103","author":"DS Chi","year":"2006","unstructured":"Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559\u201364. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.051.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"8507_CR28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","volume":"21","author":"GC Stuart","year":"2011","unstructured":"Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian Cancer consensus conference. Int J Gynecol Cancer. 2011;21(4):750\u20135. https:\/\/doi.org\/10.1097\/IGC.0b013e31821b2568.","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"8507_CR29","first-page":"2495","volume":"36","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan To Kagaku Ryoho. 2009;36(13):2495\u2013501.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"4","key":"8507_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8507_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"issue":"13","key":"8507_CR32","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.55.9898.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8507_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127(3):502\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2012.09.020.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"8507_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jso.21448","volume":"101","author":"JH Kim","year":"2010","unstructured":"Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101(2):149\u201355. https:\/\/doi.org\/10.1002\/jso.21448.","journal-title":"J Surg Oncol"},{"issue":"1","key":"8507_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/02656736.2014.991766","volume":"31","author":"MA Rettenmaier","year":"2015","unstructured":"Rettenmaier MA, Mendivil AA, Abaid LN, Brown Iii JV, Wilcox AM, Goldstein BH. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. Int J Hyperth. 2015;31(1):8\u201314. https:\/\/doi.org\/10.3109\/02656736.2014.991766.","journal-title":"Int J Hyperth"},{"issue":"5","key":"8507_CR36","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135. https:\/\/doi.org\/10.1245\/s10434-014-4157-9.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"8507_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0019-509X.138304","volume":"51","author":"N Dharmadhikari","year":"2014","unstructured":"Dharmadhikari N, Shah R, Jagannath P. Initial experience with hyperthermic intra peritoneal chemotherapy and cytoreductivesurgery. Indian J Cancer. 2014;51(2):189\u201392. https:\/\/doi.org\/10.4103\/0019-509X.138304.","journal-title":"Indian J Cancer"},{"issue":"2","key":"8507_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ygyno.2019.01.025","volume":"153","author":"SL Lim","year":"2019","unstructured":"Lim SL, Havrilesky LJ, Habib AS, Secord AA. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol. 2019;153(2):376\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.025.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8507_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","volume":"140","author":"JJ Mueller","year":"2016","unstructured":"Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016;140(3):436\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2016.01.008.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8507_CR40","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/02656736.2018.1518544","volume":"35","author":"O Le Saux","year":"2018","unstructured":"Le Saux O, Decullier E, Freyer G, Glehen O, Bakrin N. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperth. 2018;35(1):652\u20137. https:\/\/doi.org\/10.1080\/02656736.2018.1518544.","journal-title":"Int J Hyperth"},{"issue":"5","key":"8507_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/02656736.2017.1283066","volume":"33","author":"RA Cowan","year":"2017","unstructured":"Cowan RA, O'Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperth. 2017;33(5):548\u201353. https:\/\/doi.org\/10.1080\/02656736.2017.1283066.","journal-title":"Int J Hyperth"},{"issue":"4","key":"8507_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.soc.2012.07.007","volume":"21","author":"CW Helm","year":"2012","unstructured":"Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 2012;21(4):645\u201363. https:\/\/doi.org\/10.1016\/j.soc.2012.07.007.","journal-title":"Surg Oncol Clin N Am"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08507-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T13:02:33Z","timestamp":1624798953000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08507-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8507"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08507-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Human Ethics Committee of Henan Provincial People\u2019s Hospital in China, and written informed consent was obtained from each patient prior to all treatment procedures. Patients were informed that the resected specimens were stored by the hospital and potentially used for scientific research, and that privacy would be maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"738"}}